BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17150260)

  • 1. Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system.
    Larsen BT; Campbell WB; Gutterman DD
    Trends Pharmacol Sci; 2007 Jan; 28(1):32-8. PubMed ID: 17150260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man.
    Revermann M
    Curr Opin Pharmacol; 2010 Apr; 10(2):173-8. PubMed ID: 20079692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging role of epoxyeicosatrienoic acids in coronary vascular function.
    Larsen BT; Gutterman DD; Hatoum OA
    Eur J Clin Invest; 2006 May; 36(5):293-300. PubMed ID: 16634832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of epoxyeicosatrienoic acids in vascular regulation and cardiac preconditioning.
    Gauthier KM; Yang W; Gross GJ; Campbell WB
    J Cardiovasc Pharmacol; 2007 Dec; 50(6):601-8. PubMed ID: 18091575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation.
    Oltman CL; Weintraub NL; VanRollins M; Dellsperger KC
    Circ Res; 1998 Nov; 83(9):932-9. PubMed ID: 9797342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epoxyeicosatrienoic acids function as selective, endogenous antagonists of native thromboxane receptors: identification of a novel mechanism of vasodilation.
    Behm DJ; Ogbonna A; Wu C; Burns-Kurtis CL; Douglas SA
    J Pharmacol Exp Ther; 2009 Jan; 328(1):231-9. PubMed ID: 18836067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function.
    Spector AA; Fang X; Snyder GD; Weintraub NL
    Prog Lipid Res; 2004 Jan; 43(1):55-90. PubMed ID: 14636671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The factor in EDHF: Cytochrome P450 derived lipid mediators and vascular signaling.
    Fleming I
    Vascul Pharmacol; 2016 Nov; 86():31-40. PubMed ID: 26975734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of cytochrome P450 metabolites of arachidonic acid in coronary venous plasma during ischemia and reperfusion in dogs.
    Nithipatikom K; DiCamelli RF; Kohler S; Gumina RJ; Falck JR; Campbell WB; Gross GJ
    Anal Biochem; 2001 May; 292(1):115-24. PubMed ID: 11319825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases.
    Zordoky BN; El-Kadi AO
    Pharmacol Ther; 2010 Mar; 125(3):446-63. PubMed ID: 20093140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epoxyeicosatrienoic acids, cell signaling and angiogenesis.
    Fleming I
    Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):60-7. PubMed ID: 17164133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.
    Xu X; Zhang XA; Wang DW
    Adv Drug Deliv Rev; 2011 Jul; 63(8):597-609. PubMed ID: 21477627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular pharmacology of epoxyeicosatrienoic acids.
    Pfister SL; Gauthier KM; Campbell WB
    Adv Pharmacol; 2010; 60():27-59. PubMed ID: 21081214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DiscrEET regulators of homeostasis: epoxyeicosatrienoic acids, cytochrome P450 epoxygenases and vascular inflammation.
    Fleming I
    Trends Pharmacol Sci; 2007 Sep; 28(9):448-52. PubMed ID: 17764757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelium-derived epoxyeicosatrienoic acids and vascular function.
    Fleming I; Busse R
    Hypertension; 2006 Apr; 47(4):629-33. PubMed ID: 16490839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increases in levels of epoxyeicosatrienoic and dihydroxyeicosatrienoic acids (EETs and DHETs) in liver and heart in vivo by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and in hepatic EET:DHET ratios by cotreatment with TCDD and the soluble epoxide hydrolase inhibitor AUDA.
    Diani-Moore S; Ma Y; Gross SS; Rifkind AB
    Drug Metab Dispos; 2014 Feb; 42(2):294-300. PubMed ID: 24311719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble epoxide hydrolase: a promising therapeutic target for cardiovascular diseases.
    Ni GH; Chen JF; Chen XP; Yang TL
    Pharmazie; 2011 Mar; 66(3):153-7. PubMed ID: 21553642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of dronedarone, amiodarone and their active metabolites on sequential metabolism of arachidonic acid to epoxyeicosatrienoic and dihydroxyeicosatrienoic acids.
    Karkhanis A; Tram NDT; Chan ECY
    Biochem Pharmacol; 2017 Dec; 146():188-198. PubMed ID: 28958841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EETs/sEH in diabetes and obesity-induced cardiovascular diseases.
    Huang H; Weng J; Wang MH
    Prostaglandins Other Lipid Mediat; 2016 Sep; 125():80-9. PubMed ID: 27184755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of cytochrome P450-dependent transient receptor potential V4 activation in flow-induced vasodilatation.
    Loot AE; Popp R; Fisslthaler B; Vriens J; Nilius B; Fleming I
    Cardiovasc Res; 2008 Dec; 80(3):445-52. PubMed ID: 18682435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.